Compare CNTY & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTY | MAIA |
|---|---|---|
| Founded | 1992 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.1M | 49.3M |
| IPO Year | 1996 | 2022 |
| Metric | CNTY | MAIA |
|---|---|---|
| Price | $1.50 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | 28.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.53 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $2.20 | N/A |
| Revenue Next Year | $7.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.23 | $0.87 |
| 52 Week High | $2.85 | $3.19 |
| Indicator | CNTY | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 37.04 |
| Support Level | $1.48 | $1.20 |
| Resistance Level | $1.56 | $1.69 |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 29.03 | 11.57 |
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has three reportable segments based on the geographical locations in which its casinos operate; United States; Century Casino & Hotel-Central City, and Century Casino & Hotel-Cripple Creek in Colorado, Mountaineer Casino, Racetrack & Resort in West Virginia, and Century Casino Caruthersville, and Century Casino Cape Girardeau in Missouri, Canada; Century Casino & Hotel, Century Casino St. Albert, Century Mile Racetrack in Edmonton and Casino Century Downs Racetrack and Casino in Calgary, and Poland; Casinos Poland.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.